Achilles Therapeutics Plc Stock Analysis

Achilles Stock Analysis Notes

About 59.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.43. Some equities with similar Price to Book (P/B) outperform the market in the long run. Achilles Therapeutics PLC recorded a loss per share of 1.66. The entity had not issued any dividends in recent years. Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company was founded in 2016 and is headquartered in London, the United Kingdom. Achilles Therapeutics is traded on NASDAQ Exchange in the United States. For more info on Achilles Therapeutics PLC please contact Iraj Ali at 44 20 8154 4600 or go to https://www.achillestx.com.

Achilles Therapeutics PLC Investment Alerts

Achilles Therapeutics PLC Upcoming and Recent Events

Achilles Largest EPS Surprises

View All Earnings Estimates

Achilles Stock Institutional Investors

Note, although Achilles Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Achilles Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 45.71 M.

Achilles Profitablity

Management Efficiency

Achilles Therapeutics PLC has return on total asset (ROA) of (0.2682) % which means that it has lost $0.2682 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4422) %, meaning that it created substantial loss on money invested by shareholders. Achilles Therapeutics' management efficiency ratios could be used to measure how well Achilles Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.45. The value of Return On Capital Employed is expected to slide to -0.55. At this time, Achilles Therapeutics' Other Current Assets are quite stable compared to the past year. Total Current Assets is expected to rise to about 170.7 M this year, although the value of Other Assets will most likely fall to 0.95.

Technical Drivers

As of the 1st of December, Achilles Therapeutics shows the risk adjusted performance of 0.1275, and Mean Deviation of 1.97. Achilles Therapeutics PLC technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Achilles Therapeutics PLC downside variance, kurtosis, as well as the relationship between the treynor ratio and standard deviation to decide if Achilles Therapeutics PLC is priced correctly, providing market reflects its regular price of 1.08 per share. Given that Achilles Therapeutics is a hitting penny stock territory we recommend to closely look at its total risk alpha.

Achilles Therapeutics PLC Price Movement Analysis

Achilles Therapeutics Outstanding Bonds

Achilles Therapeutics Predictive Daily Indicators

Achilles Therapeutics Forecast Models

Achilles Therapeutics' time-series forecasting models are one of many Achilles Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Achilles Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Achilles Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Achilles shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Achilles Therapeutics. By using and applying Achilles Stock analysis, traders can create a robust methodology for identifying Achilles entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Achilles analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Achilles analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Achilles Therapeutics PLC stock analysis indicators help investors evaluate how Achilles Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Achilles Therapeutics shares will generate the highest return on investment. By understating and applying Achilles Therapeutics stock analysis, traders can identify Achilles Therapeutics position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.